Replimune Group (REPL) Projected to Post Earnings on Thursday

Replimune Group (NASDAQ:REPL) is expected to issue its quarterly earnings data before the market opens on Thursday, February 13th. Analysts expect the company to announce earnings of ($0.70) per share for the quarter.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. On average, analysts expect Replimune Group to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Replimune Group Price Performance

REPL stock opened at $14.06 on Friday. The firm has a market cap of $961.99 million, a P/E ratio of -4.61 and a beta of 1.30. The firm’s fifty day moving average is $12.50 and its 200 day moving average is $11.56. Replimune Group has a 52 week low of $4.92 and a 52 week high of $17.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11.

Insiders Place Their Bets

In other news, CEO Sushil Patel sold 10,000 shares of Replimune Group stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the sale, the chief executive officer now owns 202,014 shares of the company’s stock, valued at approximately $2,509,013.88. The trade was a 4.72 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the transaction, the insider now directly owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. The trade was a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 8.80% of the company’s stock.

Analysts Set New Price Targets

REPL has been the topic of several analyst reports. HC Wainwright lifted their price objective on Replimune Group from $17.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, January 22nd. Jefferies Financial Group lifted their price target on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. Finally, BMO Capital Markets increased their price objective on Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Replimune Group currently has an average rating of “Buy” and a consensus price target of $19.14.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.